Please try another search
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Paul B. Manning | 66 | 2018 | Independent Chairman |
Paul-Peter Tak | 61 | 2020 | President, CEO & Director |
Estuardo Aguilar-Cordova | 63 | 2002 | Founder & Director |
Henry Brem | 69 | 2021 | Member of Research Advisory Board |
Scott Eggener | - | - | Member of Scientific Advisory Board |
Steven M. Albelda | - | - | Member of Scientific Advisory Board |
Daniel H. Sterman | - | - | Member of Scientific Advisory Board |
Padmanee Sharma | - | 2021 | Member of Research Advisory Board |
Philip W. Kantoff | 67 | 2021 | Member of Research Advisory Board |
Patrick Yung Wen | - | - | Member of Scientific Advisory Board |
E. Antonio Chiocca | - | - | Member of Scientific Advisory Board |
James Patrick Allison | - | 2021 | Member of Research Advisory Board |
Charu Aggarwal | - | - | Member of Scientific Advisory Board |
Tri Le | - | - | Member of Scientific Advisory Board |
Mark Bloomston | - | - | Member of Scientific Advisory Board |
Diem Nguyen | 50 | 2021 | Independent Director |
Adam Kibel | - | - | Member of Scientific Advisory Board |
Christopher Martell | 43 | 2018 | Independent Director |
Edward J. Benz | 76 | 2017 | Member of Research Advisory Board & Director |
Renee M. Gaeta | 41 | 2022 | Independent Director |
Joseph C. Papa | 66 | 2022 | Independent Director |
Nicoletta Loggia | - | 2023 | Independent Director |
Gary J. Nabel | 69 | 2022 | Member of Research Advisory Board & Director |
Roy Steven Herbst | 61 | 2021 | Member of Research Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review